Biosimilars: US FDA Developing Guidance For First Interchangeable Exclusivity
Executive Summary
The first biosimilar with interchangeability status compared to its reference will be entitled to one year of exclusivity, a largely overlooked advantage in the early days of the US biosimilar market.
You may also be interested in...
Could US FDA User Fee Bill Include The Long-Sought 505(b)(2) Pathway For Biosimilars?
Former FDA official says the pathway is needed to avoid wasted sponsor time and effort.
Could US FDA User Fee Bill Include The Long-Sought 505(b)(2) Pathway For Biosimilars?
Former FDA official says the pathway is needed to avoid wasted sponsor time and effort.
Tentative Biosimilar Approvals Under Consideration By FDA
Concept could help sponsors who reach approvability but must wait several years before reference product exclusivity expires.